Status:
TERMINATED
Weekly Topotecan With Docetaxel in Recurrent Small Cell Lung Cancer
Lead Sponsor:
Aultman Health Foundation
Collaborating Sponsors:
GlaxoSmithKline
Conditions:
Mediastinal Neoplasms
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
The purposes of this study are: * To determine the overall response rate of patients treated with at least 2 cycles of this regimen. * To determine the feasibility and toxicity of the combination of ...
Detailed Description
The main objective of this study was to determine the overall response rate of patients treated with at least 2 cycles of topotecan and docetaxel. The secondary objectives were to determine the feasib...
Eligibility Criteria
Inclusion
- Recurred greater than 90 days after initial treatment
- At least 1 measurable lesion
- Only 1 prior chemotherapy
- Must be over 18 years of age
- ECOG performance status of 0 - 2
- Adequate hematologic, renal, and hepatic function
Exclusion
- No prior use of topotecan, docetaxel, or irinotecan
- No symptomatic brain metastases
- History of cardiac arrhythmias, congestive heart failure, stroke, or embolic events
- No prior investigational agents within 1 month prior
- Lung cancer of mixed histology
- Known uncontrolled seizure disorders
Key Trial Info
Start Date :
November 1 2004
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 8 2007
Estimated Enrollment :
7 Patients enrolled
Trial Details
Trial ID
NCT00315211
Start Date
November 1 2004
End Date
November 8 2007
Last Update
August 20 2018
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Aultman Hospital
Canton, Ohio, United States, 44710